Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.
about
Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK geneTERT promoter mutations in thyroid cancerGenomically driven precision medicine to improve outcomes in anaplastic thyroid cancerProgress in molecular-based management of differentiated thyroid cancerRAS mutations in thyroid cancermiRNA expression and function in thyroid carcinomas: a comparative and critical analysis and a model for other cancersModulation of inflammation by autophagy: Consequences for human diseaseAutophagy in thyroid cancer: present knowledge and future perspectivesOxidative stress: a new risk factor for thyroid cancerMolecular Evolution of PTEN Pseudogenes in MammalsSphingosine kinase 1 is overexpressed and promotes proliferation in human thyroid cancer.Relative quantification of PIK3CA gene expression level in fine-needle aspiration biopsy thyroid specimens collected from patients with papillary thyroid carcinoma and non-toxic goitre by real-time RT-PCR.The emerging role of pseudogene expressed non-coding RNAs in cellular functionsEvaluation of PTEN, PI3K, MTOR, and KRAS expression and their clinical and prognostic relevance to differentiated thyroid carcinomaCopy number alteration and uniparental disomy analysis categorizes Japanese papillary thyroid carcinomas into distinct groups.RASAL1 in thyroid cancer: promise from a new friend.Molecular pathogenesis and mechanisms of thyroid cancerA pseudogene long-noncoding-RNA network regulates PTEN transcription and translation in human cellsSingle nucleotide polymorphism rs17849071 G/T in the PIK3CA gene is inversely associated with follicular thyroid cancer and PIK3CA amplification.Multikinase inhibitors use in differentiated thyroid carcinoma.The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway.The role of epigenetic alterations in papillary thyroid carcinogenesis.Expression, localization, and phosphorylation of Akt1 in benign and malignant thyroid lesionsThe variable phenotype and low-risk nature of RAS-positive thyroid nodules.The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cellsClinical significance of BRAF V600E mutation in 154 patients with thyroid nodules.Modeling follicular thyroid cancer for future therapiesClinical utility of RAS mutations in thyroid cancer: a blurred picture now emerging clearer.Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAF(V600E) or wild-type BRAFMouse models of follicular and papillary thyroid cancer progression.Anaplastic thyroid carcinomaTrametinib with and without pazopanib has potent preclinical activity in thyroid cancer.Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis.Mitochondrial Metabolism as a Treatment Target in Anaplastic Thyroid Cancer.Contactin 1 as a potential biomarker promotes cell proliferation and invasion in thyroid cancerThe role of phosphoinositide 3-kinase subunits in chronic thyroiditis.REC8 is a novel tumor suppressor gene epigenetically robustly targeted by the PI3K pathway in thyroid cancer.Mutations in critical domains confer the human mTOR gene strong tumorigenicity.Recent insights into the cell biology of thyroid angiofollicular units.Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.
P2860
Q24598210-DD301D64-5992-435D-9507-54A8A030A96DQ26770808-9A6C34E7-C3E8-41B9-A74A-5301AF631507Q26820880-695229AD-07AF-461D-88DC-8CF04CEAAF96Q26999887-E57C5A39-B118-4DD9-B0D6-EC47E8EDC36DQ27026163-C8EA32EE-AA7B-4184-9576-0B02294E8F98Q28078451-8D7C3E70-C7A4-43D9-8AB7-93E3A41A2D68Q28082840-D64510D9-2E65-427E-B4D1-E3E7F725E3FCQ28086785-F637DF8C-6AAD-4877-A6B3-E30626AB8CAFQ28388902-5A42BC40-4816-4C1C-9266-21658BEE8585Q28588224-A2CB818A-01C0-4DD0-8257-97274D00A178Q33636769-F1277539-F27E-48D4-89DB-D91DB43C7A5AQ34128087-71CD8C04-53AB-4630-AF07-B6C27119B799Q34160931-A61297E9-5CBC-4140-A8B5-1AEEA21A96EFQ34226772-F039C507-85C5-4886-9629-20E71C835A4BQ34257114-1FCA2887-2854-425F-A1D0-149C765D4250Q34284826-6042DD12-432E-4B37-82C6-BB0EE2E77E9EQ34329018-0A1AB162-B859-41F2-947D-C4A13D646407Q34329463-97EFF5B9-3FB3-4377-B796-B7445BD8830DQ34489924-0F8735F5-93C6-4799-92B2-62F6E1F8BF5DQ34660901-71B9A93F-8664-45AF-A76D-AB5ED251B1ACQ34758583-30F9E94B-8033-408C-8E5E-E343A0A56881Q35099482-63B1356E-CD83-40BB-BE68-A6A8087011A5Q35589717-42E0C213-60C1-4010-83BF-8A66E7546BCDQ35740151-C425271B-A2C6-4665-97D9-56259A003D0BQ35744471-041CDFA0-CA09-4FD1-B920-631CEE0E7F15Q35758471-77FD09AE-0797-4EC2-A45B-0A9E58E2DCBBQ35832908-C09B157E-F4B1-4747-B996-1030D345D3ABQ35906046-0CD20D79-B34B-4DDB-98D0-064A719404BDQ35914464-BC4BBAF5-FED8-4134-9E72-7F75032BD42EQ35971896-C2DF6795-408B-4DF2-A487-F34C3730C400Q36075843-8129B28D-E2A8-48E9-B950-E2A9D28D82A7Q36094108-F051D097-E3CA-49EC-B528-CA4313426BD6Q36255616-1B8DD707-F60B-4AEC-9A50-19F7CF6257F6Q36328030-5CCFA2C3-BA5B-473A-B291-1CBF0DD8BD91Q36375125-DD99DCBA-34CE-451A-9B20-BA78FB384DEEQ36523759-9575B057-7B38-4C65-88AF-A536AFB3F998Q36629559-5A51E9F2-A28A-47B9-A5D3-8060834B7C54Q36647365-6F11A33E-4AF9-4B96-8A08-B98457413583Q36724051-9A964C84-342B-4D30-B5FF-1BB92CF307E7Q36788057-F677F285-DBAA-47EA-9BDD-85AF09C487B5
P2860
Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.
@en
Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.
@nl
type
label
Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.
@en
Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.
@nl
prefLabel
Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.
@en
Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.
@nl
P2860
P356
P1433
P1476
Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.
@en
P2093
Mingzhao Xing
P2860
P304
P356
10.1089/THY.2010.1646
P577
2010-07-01T00:00:00Z